Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Cash & Current Investments (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Cash & Current Investments data on record, last reported at $61.0 million in Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 27.51% year-over-year to $61.0 million; the TTM value through Dec 2025 reached $61.0 million, up 27.51%, while the annual FY2025 figure was $61.0 million, 27.51% up from the prior year.
  • Cash & Current Investments reached $61.0 million in Q4 2025 per LCTX's latest filing, up from $40.5 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $97.1 million in Q4 2022 and bottomed at $30.0 million in Q4 2023.
  • Average Cash & Current Investments over 5 years is $54.2 million, with a median of $47.8 million recorded in 2024.
  • Peak YoY movement for Cash & Current Investments: soared 239.47% in 2021, then plummeted 69.13% in 2023.
  • A 5-year view of Cash & Current Investments shows it stood at $65.1 million in 2021, then skyrocketed by 49.21% to $97.1 million in 2022, then tumbled by 69.13% to $30.0 million in 2023, then skyrocketed by 59.43% to $47.8 million in 2024, then increased by 27.51% to $61.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $61.0 million in Q4 2025, $40.5 million in Q3 2025, and $42.3 million in Q2 2025.